Dravet syndrome associated with SCN1A mutation: case report with therapeutic response to cannabidiol
Abstract
Case Presentation: Dravet syndrome is a rare developmental and epileptic encephalopathy characterized by early-onset drug-resistant seizures and progressive neurological deterioration. Most cases are associated with SCN1A mutations, which encode the neuronal sodium channel NaV1.1, essential for inhibitory GABAergic interneuron function. Early recognition is critical for appropriate diagnosis and management. A 15 year old female presented with seizure onset at 6 months after a febrile episode, evolving with a prolonged tonic-clonic seizure (30 minutes). She subsequently developed high seizure frequency (up to 30/day), requiring hospitalization. Pharmacoresistance to multiple antiseizure medications was observed, including phenobarbital, valproate, levetiracetam, clonazepam, and topiramate, with only partial control under polytherapy. Over time, she developed multiple seizure types (absence, myoclonic, tonic-clonic, and catamenial) and significant global developmental delay, including late independent walking (8 years), hypotonia, and severe expressive language impairment. EEG showed diffuse epileptiform activity, background disorganization and periods of burst suppression. Genetic testing in 2025 identified a heterozygous pathogenic SCN1A variant, confirming Dravet syndrome. Cannabidiol (20 mg/mL) was initiated, leading to marked reduction in seizure frequency (from 30/day to one every 3 days), with clinical improvement. She remains under follow-up on combined therapy including cannabidiol. Discussion: This case reflects the typical course of Dravet syndrome, with early onset, febrile seizures, and progression to refractory epilepsy with neurodevelopmental impairment. SCN1A mutations impair inhibitory interneurons, leading to neuronal hyperexcitability. Genetic testing is essential for diagnosis and therapeutic guidance. EEG findings typically evolve to diffuse epileptiform abnormalities. Management remains challenging; however, therapies such as cannabidiol have demonstrated efficacy in reducing seizure frequency in pharmacoresistant epilepsies. Final Comments: This case highlights the importance of early recognition and genetic diagnosis in Dravet syndrome and supports cannabidiol as an effective adjunctive therapy, with substantial reduction in seizure burden and clinical improvement.